Disease Markers / 2013 / Article / Tab 2

Research Article

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum

Table 2

Patient demographics and effusion mesothelin and MPF concentrations in MM patients and controls.

GroupNumber of cases (number of females)Mean age, years (range)Effusion mesothelin (nM)a,cEffusion MPF (ng/mL)a,b,c

MM43 (6)71 (42–88)
Non-MM malignant effusions79 (47)70 (37–96)
 Lung cancer42 (17)72 (48–92)
 Breast cancer19 (19)65 (37–96)
 Ovarian cancer11 (11)66 (42–86)
 Pancreatic cancer7 (0)64 (56–75)
Benign effusions143 (39)66 (1996)
 ARD16 (1)74 (50–91)
 Exudate51 (12)65 (19–94)
 Infection42 (10)64 (30–96)
 Transudate34 (16)71 (12–93)

exponentiated mean of log transformed data plus/minus standard error of log transformed data *100.
bMPF concentrations determined from Human MPF Assay (MBL).
csignificant difference between indicated cohorts and mesothelioma group as a whole ( ) as determined by Student’s -test (ns is not significant; ** is ; and *** is ).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.